Insights & news

U.S. Department of Health and Human Services Announces International Pricing Index Model to Lower U.S. Medicine Cost

  • 29/10/2018
  • Articles

On 25 October 2018, the U.S. Department of Health and Human Services (“HHS”) announced the International Pricing Index (“IPI”) Model as a new tool to lower the cost of physician-administered medicines in the U.S.. According to HHS, the IPI Model is based on international prices of medicines and on a degree of competition in the value chain between medicine suppliers and healthcare providers introduced by private-sector vendors. It will now form the subject of public consultations.

The international pricing component stems from findings in an HHS study that the US is paying 1.8 times as much as a range of other wealthy countries for medicines. For 19 of 27 products studied, the U.S. paid more than any of the other countries “with similar economic conditions” under review. To remedy what President Trump calls “foreign freeloading” resulting from supposedly extortionist pricing practices vis-à-vis US medicine producers, the IPI Model will set a sample of medicines at a Target Price which, in turn, will be determined on the basis of discounts given by medicine firms to other countries. The Target Price will amount to 126% of the average price which other countries pay for a given medicine. The Model will be phased in over 5 years and will start in 50% of the U.S. before being scaled up.

The HHS study underpinning the IPI Model includes 14 EU countries, Canada and Japan. The EU countries mirror Germany’s external reference pricing basket (minus Denmark and The Netherlands). The products selected are, broadly, the top 20 medicines sold under the Medicare programme for the elderly, including single-source medicines, biological medicines and biosimilar products.

One of the stated goals of the IPI Model is to “[a]ddress the disparity in drug prices between the U.S. and other countries”. While it is clear this effort is expected to lead to lower medicine prices in the U.S. (overall savings for U.S. taxpayers and patients are projected to total $17.2 billion over a period of 5 years), higher medicine prices overseas (or, alternatively, a reduction in the availability of specific medicines in foreign countries) cannot be ruled out.

The IPI Model follows the May 2018 publication of the U.S. government policy paper “American Patients First” which had already decried the “foreign governments’ free-riding off American investment in innovation” (see, our article of 14 May 2018).

The following publications are attached by way of background:

  • HHS study “Comparison of U.S. and International Prices for Top Medicare Part B Drugs by Total Expenditures” – 25 October 2018;
  • HHS press release “HHS Advances Payment Model to Lower Drug Costs for Patients” – 25 October 2018;
  • HHS press release “What You Need to Know about President Trump Cutting Down on Foreign Freeloading” – 25 October 2018;
  • Advance Notice of Proposed Rulemaking “International Pricing Index Model for Medicare Part B Drugs” – undated; not yet published in Federal Register.

Key contacts

Related insights

Sign up for updates
    • 12/03/2019
    • Articles

    Belgium – New legislation in the making on cannabis for medical use

    In light of the growing international scientific consensus on the positive medicinal effects of cannabis, Belgian lawmakers have tabled proposed legislation which, if adopted, would make the use of cannabis for medical purposes legal. A Cannabis Office will be created within the Federal Agency for Medicines and Health Products which will be in charge of the legal production of medical cannabis, establishing a monopoly for the Belgian State on the cultivation, trade, import and export of that product. Other EU member states already have followed a similar legislative route (e.g. the Netherlands). Following the establishment of the Cannabis Office, a call for tenders will be issued for the cultivation of a certain amount of cannabis. Licences will be granted to the successful applicants to cultivate cannabis in specified locations. The Cannabis Office will purchase the harvest and export and/or distribute it. The manufacturing process will be subject to stringent standards. For example, the cannabis will need to have a stable concentration of the active substance as well as a stable ratio of the main active ingredients, i.e. cannabidiol (CBD) and the main psychoactive compound tetrahydrocannabinol (THC). The move comes more than three years after the first cannabis-based medicine (Sativex spray) became authorized and reimbursable in Belgium for certain multiple sclerosis (“MS”) patients. If physicians want to prescribe medicinal cannabis to their patients for pain relief, or the treatment of nausea and reduced appetite during chemotherapy, further regulatory changes will be required.

    Read more
    • 08/03/2019
    • Articles

    Belgium - Bill Tackles Medicine Shortages

    A number of members of parliament introduced last week a private members’ bill that has the twin objectives of tackling medicine shortages and combating the trade in falsified medicines (bill 54 3599/001 – the “Bill” – see attached). Medicine Shortages The Bill will modify the Law of 25 March 1964 to (i) allow the concept of “temporary cessation of supply of medicines” to be determined by Royal Decree; (ii) allow the Minister to make recommendations of suitable therapeutical alternatives in case of temporary shortages of specific medicines; (iii) preclude wholesalers (“WS”) with a public-service WS status from supplying ordinary WS; and (iv) impose particular shortage-related obligations on parallel traders which previously only applied to the marketing authorisation holders. The proposed ban on public-service WS to supply ordinary WS (and therefore limit their supplies to, broadly, other public-service WS, pharmacists and hospitals) is designed to ensure the steady supply of medicines to the local market and, conversely, cut down on exports that threaten public health. Under specific conditions, the ban will not apply to medicines earmarked for clinical trials. Falsified Medicines The Bill establishes criminal sanctions for specific violations of Regulation 2016/161 which lays down safety features for the packaging of medicines for human use. The current caretaker government no longer commands a majority in the federal Chamber of Representatives. However, the Bill may be assured of an ad hoc majority in that it has already been given a time slot in the session of the committee for public health scheduled on 12 March 2019.

    Read more
    • 04/03/2019
    • Articles

    Belgian Competition Authority Will Again Focus on Pharmaceuticals in 2019

    On 1 March 2019, the Belgian Competition Authority published its yearly policy note setting out its enforcement priorities for the year (see attachments). As was the case in previous years, the pharmaceutical sector is one of the BCA’s main targets for action. Once more, the BCA indicates that it deliberately emulates the approach of other national competition authorities in focusing on “all links of the value chain, including prices charged by pharmaceutical firms, competition between distributors with public-service obligations, the competitive dynamics and innovation at the pharmacy level”. Given the pending inquiries in the sector, this announcement again does not come as a surprise. It also reflects the general competition scrutiny of the sector in Europe, as was evidenced by the publication in January 2019 of the Competition Pharmaceutical Enforcement Report by the European Commission (see, Van Bael & Bellis Life Sciences Newsflash of 28 January 2019). In other news relevant to the sector, the BCA also confirms its continued attention to public procurement. Apart from the pharmaceutical sector, the BCA will target telecommunications, distribution, service providers and logistics. All in all, this year’s enforcement priorities closely resemble those applying in 2018.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *